1.55
price down icon0.64%   -0.01
pre-market  プレマーケット:  1.53   -0.02   -1.29%
loading
前日終値:
$1.56
開ける:
$1.61
24時間の取引高:
148.48K
Relative Volume:
0.08
時価総額:
$3.54M
収益:
$644.60K
当期純損益:
$-9.87M
株価収益率:
-0.00185
EPS:
-837.9618
ネットキャッシュフロー:
$-9.02M
1週間 パフォーマンス:
+8.39%
1か月 パフォーマンス:
-2.52%
6か月 パフォーマンス:
-75.44%
1年 パフォーマンス:
-91.45%
1日の値動き範囲:
Value
$1.52
$1.65
1週間の範囲:
Value
$1.2396
$1.65
52週間の値動き範囲:
Value
$1.14
$74.00

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
名前
Biodexa Pharmaceuticals Plc Adr
Name
セクター
Healthcare (1155)
Name
電話
-
Name
住所
-
Name
職員
13
Name
Twitter
Name
次回の収益日
2024-06-13
Name
最新のSEC提出書
Name
BDRX's Discussions on Twitter

BDRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
1.55 3.54M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-02-08 開始されました Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース

pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Jan 30, 2025

Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 03, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN

Jan 03, 2025
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN

Dec 29, 2024
pulisher
Nov 28, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register

Nov 28, 2024
pulisher
Nov 22, 2024

Result of General Meeting - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart

Nov 21, 2024
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
pulisher
Nov 07, 2024

Notice of General Meeting - StockTitan

Nov 07, 2024
pulisher
Nov 01, 2024

Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks

Nov 01, 2024
pulisher
Oct 29, 2024

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan

Oct 17, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension - Investing.com

Oct 15, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com

Oct 04, 2024
pulisher
Sep 26, 2024

Interim results for the six months ended June 30, 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - GlobeNewswire

Sep 19, 2024
pulisher
Sep 16, 2024

Biodexa secures full access to cancer research grant - Investing.com

Sep 16, 2024
pulisher
Aug 30, 2024

Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan

Aug 30, 2024
pulisher
Jul 19, 2024

Biodexa Pharmaceuticals sets $5 million offering - Investing.com

Jul 19, 2024
pulisher
Jul 17, 2024

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Jul 17, 2024
pulisher
Jul 16, 2024

Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks

Jul 16, 2024
pulisher
Jul 11, 2024

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan

Jul 11, 2024
pulisher
May 21, 2024

Biodexa’s eRapa Shows Promise in FAP Treatment - TipRanks

May 21, 2024
pulisher
Mar 01, 2024

PRFX Stock Quote Price and Forecast - CNN

Mar 01, 2024
pulisher
Feb 09, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 09, 2024
pulisher
Jul 05, 2023

Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune

Jul 05, 2023
pulisher
Jun 27, 2023

Biodexa Pharma (BDRX) Stock Rallied 27% on Investor Interest - AskTraders.com

Jun 27, 2023
pulisher
Jun 23, 2023

Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com

Jun 23, 2023
pulisher
Mar 30, 2023

Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis - MarketBeat

Mar 30, 2023

Biodexa Pharmaceuticals Plc Adr (BDRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
大文字化:     |  ボリューム (24 時間):